

Strategies for Oral Delivery of Peptides

John Vrettos

Enteris BioPharma, Inc., 83 Fulton Street, Boonton, NJ, 07005 USA
jvrettos@enterisbiopharma.com

Presently, many peptides, peptidomimetics and related BCS class III and IV molecules can only be administered via intravenous injection due to low oral bioavailability, which can limit market opportunities for the drug maker and reduce patient compliance with drug regimens. Oral versions of these drugs would widen their market potential and provide a preferred route of administration to patients. However, significant challenges must be overcome to realize the delivery of peptides by the oral route, including protecting the API from enzymatic degradation and enabling permeation across the epithelial lining. This presentation will review some of the strategies for oral delivery of peptide drugs, including approaches employing chemical and mechanical means. Case studies of Enteris BioPharma's experience with oral peptide delivery will be discussed.